Chinese state-owned Sinopharm Group Co., Ltd.'s subsidiary, China National Biologics Products Group has commenced a Phase III study for its vaccine against the coronavirus in Abu Dhabi, via a partnership with locally-based G42 Healthcare and carried out by Abu Dhabi Health Services.
The regulatory approval, granted by the United Arab Emirates state, allows as many as 15,000 volunteers to participate in the...







